Clinical Trial Update: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating GLSI-100 (GP2 + GM-CSF) for HER2-positive breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GLSI-100 (GP2 + GM-CSF) (GLSI-100)

Snippet

Sponsor: Greenwich LifeSciences, Inc. | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING